The nationwide experiment will initially include around 100,000 volunteers.
Charles Nemeroff, who was barred from receiving grants for 2 years in 2008, snags $401K from the NIH to study PTSD.
August 14, 2012|
In December 2008, psychiatrist Charles Nemeroff, then at Emory University, was sanctioned for not disclosing more than $1 million from drug companies to promote their products in academic publications. His punishment: Emory barred him from receiving grants for 2 years. But those 2 years have come and gone, and in May, the National Institutes of Health (NIH) awarded Nemeroff, now at the University of Miami, a 5-year, $401,675-a-year grant to study posttraumatic stress disorder.
Shortly after the grant was announced, however, Senator Charles Grassley (R-IA), an activist for public disclosure of financial relationships in the biomedical fields, wrote a letter to the NIH questioning the decision. “Please explain how the NIH arrived at this decision to award Dr. Nemeroff despite past ethical problems,” Grassley wrote. “Although NIH has recently revamped its conflict of interest guidelines, this decision risks sending the wrong message to physicians seeking or performing federally funded research.” Furthermore, he noted, the Department of Health and Human Services’s Office of Inspector General (OIG) and the Department of Justice (DOJ) have been collaborating on an investigation of Nemeroff, and the results of that query have yet to be released.
Earlier this month, NIH Deputy Director Lawrence Tabak responded to Grassley, the blog Pharmalot reported. He explained that peer reviewers weren't told about the OIG and DOJ investigations because they are confidential. "Absent any finding by the OIG or other actionable grounds at this time to exclude Dr. Nemeroff, the NIH followed standard procedures," Tabak wrote. In addition, the NIH specifically asked the University of Miami about potential conflicts of interest, noted that the research does not involve the testing of any drugs, and stated that a reviewer that used to work with Nemeroff (Thomas Insel, director of the National Institute of Mental Health) recused himself from the review process. "I want to assure you that all procedures have been followed carefully in the process of awarding this specific grant to the University of Miami," Tabak wrote.
(Hat tip to ScienceInsider.)
August 14, 2012
The more obvious role of odors in PTSD suggests that we welcome Dr. Nemeroff back to the time when others were interested in examining the role of olfactory/pheromonal input and its epigenetic effects on behavior via the "biological core" of mammalian behavior, the hypothalamic gonadotropin releasing hormone (GnRH) neuronal niche, as in:
Moss, R. L., Dudley, C. A., & Riskind,
P. N. (1991). Gonadotropin releasing hormone and human sexual behavior. In C.
B. Nemeroff (Ed.), Neuropeptides and
Psychiatric Disorders. Washington, D.C: American Psychiatric Press.
Given the otherwise ignored importance of GnRH to oxytocin secretion, with reports on its cause and effect all-the-rage, even those formerly involved with social bonding and autism research can appreciate what it means to have Nemeroff back.